retatrutide and blood sugar New GLP-3 drug significantly slashes both weight levels in Phase III trial What Does Retatrutide Do?

Tirzepatide (Dual GLP-1 / GIP agonist) Examined for its ability to influence multiple metabolic receptors at once

indekiler 1

2 This is an important distinction

placebo on the time to occurrence of a composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, hospitalization or urgent visit due to heart failure) and a composite renal outcome (end-stage kidney disease, 40% sustained decline in eGFR, cardiovascular death or renal death) in 10,000 individuals with atherosclerotic cardiovascular disease and/or CKD

Industry Funding: From the study, Eli Lilly and Company sponsored the work and was involved in the study design, data collection, data review, data analysis, and drafting of the report